Ultrasound stimulation represents a rapidly evolving field that harnesses acoustic energy to non-invasively modulate neural circuitry. This approach offers exceptional spatial resolution and depth ...

Neurolief Inc., a medical device company focused on neuromodulation therapies for neuropsychiatric conditions, today ...

NEWTOWN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and ...

NEWTOWN, Pa. - Helius Medical Technologies, Inc. (NASDAQ:HSDT), a neurotech company with a market capitalization of $3.84 million, announced significant findings from the PoNS Therapeutic Experience ...

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home neuromodulation ...

NEWTOWN, Pa., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation ...

The FDA approved a prescription at-home brain neuromodulation therapy as an adjunctive depression treatment for adults, maker ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

A new study published in Neuromodulation (1) demonstrates that automatic, daily remote monitoring of spinal cord stimulation (SCS) devices enables the first real-time visibility into post-implant ...

-- Reimbursement Determination for the PoNS Mouthpiece (HCPCS code A4594) set at $2,963.30 on Lump Sum Payment to be challenged by Helius -- -- National Reimbursement Payment Determination from CMS ...

Pulsetto Bilateral Cervical Neuromodulation Device Evaluation: Session Duration, General Wellness Positioning, User-Reported ...